PREVISS: Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05177380
Collaborator
(none)
60
2
19

Study Details

Study Description

Brief Summary

Systemic sclerosis is a rare autoimmune disorder characterized by microangiopathy, activation of the immune system, and sclerosis of tissues including the skin. Facial involvement is frequent and disabling. It causes significant functional and aesthetic discomfort, and a major deterioration in quality of life. It results in a loss of suppleness of the skin and subcutaneous tissues, dysfunction of the temporomandibular joint, peribuccal rhagades, microstomia, and dry mouth causing difficulties in mouth opening, feeding, dental care, and weight loss.

Facial involvement in systemic sclerosis can be assessed using the Mouth Handicap in Systemic Sclerosis (MHISS) score, a validated patient questionnaire assessing the functional and aesthetic consequences of systemic sclerosis on the face.

Although common and disabling, facial involvement is underestimated and poorly managed. Immunosuppressive and/or anti-fibrosis drugs are not very effective. Facial rehabilitation could significantly improve the mouth handicap but facial rehabilitation is not currently performed in standard care in systemic sclerosis patients.

The aim of the study is to evaluate the efficacy of a personalized rehabilitation program vs standard care in facial involvement of systemic sclerosis patients.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Personalized rehabilitation program of facial involvement in systemic sclerosis
  • Other: Delivery of a standard prescription for facial rehabilitation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Apr 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Personalized rehabilitation program of facial involvement in systemic sclerosis

3 sessions of 2 hours of facial rehabilitation in hospital over 2 weeks including: Physiotherapy with facial and endo-oral massages, self-massages, active and passive exercises of the face and mouth, tongue exercises Speech therapy with mobilization of the orofacial sphere applied to swallowing and speech difficulties Individual workshop on the theme of dry mouth, dry mouth, swallowing disorders, and oral care Individual therapeutic makeup workshop A motivational interview A patient notebook with a personalized protocol for self-rehabilitation of the face A video tutorial for self-rehabilitation of the face Facial self-rehabilitation sessions at home

Procedure: Personalized rehabilitation program of facial involvement in systemic sclerosis
Personalized rehabilitation program of facial involvement in systemic sclerosis

Other: Routine care

Delivery of a standard prescription for facial rehabilitation

Other: Delivery of a standard prescription for facial rehabilitation
Delivery of a standard prescription for facial rehabilitation

Outcome Measures

Primary Outcome Measures

  1. Mouth Handicap In Systemic Sclerosis (MHISS) score [Week 6]

    A 12-item questionnaire specifically quantifying mouth disability in systemic sclerosis

Secondary Outcome Measures

  1. Mouth Handicap In Systemic Sclerosis (MHISS) score [Week 2]

    A 12-item questionnaire specifically quantifying mouth disability in systemic sclerosis

  2. Mouth Handicap In Systemic Sclerosis (MHISS) score [Week12]

    A 12-item questionnaire specifically quantifying mouth disability in systemic sclerosis

  3. Interincisal distance measurement [Week 6]

    Interincisal distance measurement in mm

  4. Interincisal distance measurement [Week 12]

    Interincisal distance measurement in mm

  5. Rodnan skin score on the face [Week 6]

    a measure of skin thickness

  6. Rodnan skin score on the face [Week 12]

    a measure of skin thickness

  7. Visual Analog Scale (VAS) for pain [Week 2]

  8. Visual Analog Scale (VAS) for pain [Week 6]

  9. Visual Analog Scale (VAS) for pain [Week12]

  10. HAQ questionnaire [Week 6]

    Health Assessment Questionnaire

  11. HAQ questionnaire [Week 12]

    Health Assessment Questionnaire

  12. SF12 questionnaire (12-item Short Form Survey) [Week 6]

    a 12-item general health questionnaire

  13. SF12 questionnaire (12-item Short Form Survey) [Week 12]

    a 12-item general health questionnaire

  14. Weight [Week 12]

    Weight in kg

  15. Total number of rehabilitation sessions [Week 6]

  16. Total duration of rehabilitation sessions [Week 6]

  17. Total number of rehabilitation sessions [Week 12]

  18. Total duration of rehabilitation sessions [Week 12]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18 yo

  • Systemic sclerosis according to the 2013 ACR/EULAR (American College of Rheumatology) classification criteria

  • Systemic sclerosis with facial involvement defined by a MHISS score > 6

  • Immunosuppressive and/or anti-fibrosis treatment stable for at least 1 month

  • Subject able to understand the objectives and risks of research and to give informed consent

  • Subject enrolment in the health insurance scheme

Exclusion Criteria:
  • Pregnancy

  • Previous participation in a rehabilitation program of facial involvement

  • Patient under legal protection

  • Impossibility to give clear information of subject

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Strasbourg, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT05177380
Other Study ID Numbers:
  • 8072
  • 2020-A03314-35
First Posted:
Jan 4, 2022
Last Update Posted:
Aug 18, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Strasbourg, France
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 18, 2022